Stay updated on Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial
Sign up to get notified when there's something new on the Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial page.

Latest updates to the Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial page
- Check4 days agoChange DetectedRevision tag updated from v3.6.5 to v3.6.6 at the bottom of the page, indicating a new page version. This reflects a minor maintenance update to the page’s version history rather than substantive changes to study details.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA new revision tag (v3.6.5) has been added, indicating an updated deployment. This change does not modify the study details or other visible content on the page.SummaryDifference0.1%

- Check32 days agoChange DetectedRemoved related topic entries for Prostate cancer and MedlinePlus Genetics from the page's Related Topics section, reducing cross-links to external resources; the change appears editorial and does not affect the study's design or results.SummaryDifference0.2%

- Check39 days agoChange DetectedThe page now shows an updated revision label 'Revision: v3.6.4' and adds 'Prostate cancer' as a related topic under MedlinePlus Genetics.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page footer now shows Revision: v3.6.3, replacing v3.6.2. This indicates a small release update to the study page.SummaryDifference0.1%

- Check68 days agoChange DetectedThe page's revision tag has been updated from v3.6.0 to v3.6.2, indicating a newer build of the site. This reflects a minor maintenance update and does not modify the displayed trial details.SummaryDifference0.1%

Stay in the know with updates to Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial page.